PKU Clinical Trial
Official title:
Multimodal Neuroimaging and Neurocognitive Assessment of Biomarkers and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria
The investigators will use different types of brain imaging (MRI) in patients with Phenylketonuria (PKU) who are currently not on a strict diet to test the hypothesis that there is improvement in brain circuitry and biochemistry after return to diet and/or sapropterin dihydrochloride (Kuvan).
We plan to enroll 36 subjects with PKU. They will all be counseled to follow the PKU diet.
They will be randomized to receive Kuvan. We will plan to enroll 12 in the diet alone group
and 24 in the Kuvan group with the hope of 12 being responders (as defined by a 30% drop in
blood phe levels). Those who do not have a blood response with decreased Phe will still be
evaluated for a neurological response as measured by neurocognitive testing and neuroimaging
as outlined in this protocol. All 24 in the Kuvan group will receive a 1 month trial of
Kuvan and then the responders will have their insurance cover the drug and for the non
responders Biomarin will supply Kuvan.
Aim 1: To test the hypothesis that stable patients with PKU who are not currently on diet
have specific brain biomarkers quantifiable by DTI, fMRI and MRS and that the levels of
these biomarkers correlate with the clinical severity and outcome. Our pilot study and the
research of others have suggested the following as potential biomarkers for neural injury in
PKU:
- Metabolic abnormalities: elevated Phe concentrations as measured by MRS.
- White matter microstructure: measured by apparent diffusion coefficient, (ADC), using
DTI.
- Working memory and attention/executive function: measured by fMRI, Near infrared
spectroscopy (NIRS) and neuropsychological testing.
We will study these potential biomarkers in a group of well characterized adults with PKU
who are not currently on diet or a strict diet as evidenced by elevated Phe, but who were
identified by the newborn screen and may have been on diet during childhood, with varying
severity of clinical involvement.
Aim 2: To measure changes in biomarkers validated in Aim 1 after return to diet +/- Kuvan
(sapropterin dihydrochloride; Kuvan)
Based on our preliminary data and that of others, Aim 1 should provide us with a number of
candidate biomarkers for brain injury in PKU. We expect that these will include three types
of markers that can be correlated: metabolic, structural and cognitive. We will use these
biomarkers to study subjects during return to diet and/or initiation of Kuvan.
Aim 3: To compare cognitive performance in our subjects prior to and after return to diet
+/- Kuvan. using the following tests:
Comprehensive Trail making test (CTMT) -Parts A and B Stroop WASI (IQ, digit span) BRIEF
Edinburgh Handedness Inventory Hand Preference Demonstration Test
Outcome variables The primary endpoints in this study are 1) an estimate of the white matter
damage (macroscopic and microscopic) in participants with PKU versus controls at baseline
and after return to diet +/- Kuvan; 2) determination of a profile of brain biochemical
abnormalities in participants with PKU versus controls at baseline and after return to
diet/Kuvan, 3) assessment of cognitive and motor systems abnormalities (by fMRI and
cognitive testing) in the participant cohort as compared to age matched typically developing
non disease controls at baseline and after return to diet/Kuvan; 4) coefficient of
variability of scoring on traditional neurocognitive.
After the conclusion of this study, future areas of research would include expansion to
study long term effects of Kuvan, study of more impaired populations and response to Kuvan,
and using optical imaging methods we are currently piloting in OTCD.
Method to investigate biomarkers of disease We plan to use 1HMRS to identify markers of
disease severity such as elevations of Phe and decreases in NAA. This will be compared in
participants and normal age matched controls. Additionally, diffusion tensor imaging will
allow us to probe white matter fiber tracts that may be especially vulnerable in this
disorder selectively. Lastly, fMRI may identify regions of differential activation in the
brain that are different in participants versus age matched controls at rest and with a
cognitive task probing working memory and attention.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02212288 -
Antioxidant Signature in Adult Patients With Phenylketonuria
|
Phase 4 | |
| Completed |
NCT05062226 -
GMP Case Studies of Tolerance, Safety and Acceptability in PKU and TYR
|
N/A | |
| Terminated |
NCT01904708 -
Moderate Intensity Exercise and Phenylketonuria
|
N/A | |
| Completed |
NCT01619722 -
Study of a National Cohort of Adult Patients With Phenylketonuria
|
||
| Completed |
NCT03913156 -
Feeding Patterns and Practices in Young Children With PKU During the First Two Years of Life
|
N/A | |
| Recruiting |
NCT05051657 -
Evaluation of the Express Plus Range
|
N/A | |
| Completed |
NCT04309331 -
Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute
|
N/A | |
| Completed |
NCT04679467 -
Evaluation of PKU Sphere in Italy
|
N/A | |
| Recruiting |
NCT05995717 -
Evaluation of PKU UP
|
N/A | |
| Completed |
NCT04318509 -
Market Research - Acceptability Study for a New PKU Protein Substitute
|
N/A | |
| Terminated |
NCT04768348 -
Natural History Clinical Study in Adult PKU
|